261 related articles for article (PubMed ID: 26797085)
41. Borderline Brenner Tumor: A Review of the Literature.
Zheng R; Heller DS
Arch Pathol Lab Med; 2019 Oct; 143(10):1278-1280. PubMed ID: 30779594
[TBL] [Abstract][Full Text] [Related]
42. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
Kim DJ; Lee MH; Park TI; Bae HI
J Korean Med Sci; 2006 Feb; 21(1):81-5. PubMed ID: 16479070
[TBL] [Abstract][Full Text] [Related]
43. Amplification of MDM2 and Loss of p16 Expression: Do They Have a Role in Malignant Transformation of Ovarian Brenner Tumor?
Wang L; Allison D; Shukla PS
Am J Clin Pathol; 2020 Jun; 154(1):133-141. PubMed ID: 32322877
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
45. Unusual presentation of benign cystic brenner tumor with exuberant psammomatous calcifications.
Vemavarapu L; Alatassi H; Moghadamfalahi M
Int J Surg Pathol; 2011 Feb; 19(1):120-2. PubMed ID: 21087980
[TBL] [Abstract][Full Text] [Related]
46. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors.
Ichikawa Y; Nishida M; Suzuki H; Yoshida S; Tsunoda H; Kubo T; Uchida K; Miwa M
Cancer Res; 1994 Jan; 54(1):33-5. PubMed ID: 8261457
[TBL] [Abstract][Full Text] [Related]
47. Mutations in the KRAS gene in ovarian tumors.
Dobrzycka B; Terlikowski SJ; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(2):221-4. PubMed ID: 19995707
[TBL] [Abstract][Full Text] [Related]
48. The Brenner tumor: a clinicopathologic review.
Balasa RW; Adcock LL; Prem KA; Dehner LP
Obstet Gynecol; 1977 Jul; 50(1):120-8. PubMed ID: 195239
[TBL] [Abstract][Full Text] [Related]
49. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
[TBL] [Abstract][Full Text] [Related]
50. Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.
Genestie C; Auguste A; Al Battal M; Scoazec JY; Gouy S; Lacroix L; Morice P; Pautier P; Leary A; Devouassoux-Shisheboran M
Virchows Arch; 2021 May; 478(5):885-891. PubMed ID: 33009577
[TBL] [Abstract][Full Text] [Related]
51. Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor.
Roma AA; Masand RP
Ann Diagn Pathol; 2015 Feb; 19(1):29-32. PubMed ID: 25596159
[TBL] [Abstract][Full Text] [Related]
52. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
53. Histogenesis of Brenner tumors, I: histology and ultrastructure.
Shevchuk MM; Fenoglio CM; Richart RM
Cancer; 1980 Dec; 46(12):2607-16. PubMed ID: 7448700
[TBL] [Abstract][Full Text] [Related]
54. MDM2 amplification in malignant Brenner tumors may play a role in progression to malignancy and aid in separation from urothelial and other ovarian carcinomas.
Shetty S; Habeeb O; Rivera C; Astbury C; Przybycin C; Joehlin-Price AS
Hum Pathol; 2021 Nov; 117():42-50. PubMed ID: 34391746
[TBL] [Abstract][Full Text] [Related]
55. k-ras mutation may be an early event in mucinous ovarian tumorigenesis.
Garrett AP; Lee KR; Colitti CR; Muto MG; Berkowitz RS; Mok SC
Int J Gynecol Pathol; 2001 Jul; 20(3):244-51. PubMed ID: 11444200
[TBL] [Abstract][Full Text] [Related]
56. Genomic analysis of primary epithelial neoplasms of the seminal vesicle identifies a subset of mucinous cystic tumours driven by KRAS mutations.
Collins K; Galea LA; Foroughi F; Siegmund SE; Anderson WJ; Appu S; Idrees MT; Ulbright TM; Acosta AM
Histopathology; 2024 Jun; 84(7):1192-1198. PubMed ID: 38409850
[TBL] [Abstract][Full Text] [Related]
57. [KRAS mutations analysis in mucinous epithelial lesions of the endometrium].
Zheng XZ; Zhan Y; Ma JH; Xu HW; Zhi WX; Chen TB; Qin XY; Wang P; Zhang LH; Gu YC; Jin YL; Zhu L; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):687-690. PubMed ID: 30220122
[No Abstract] [Full Text] [Related]
58. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF
Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233
[TBL] [Abstract][Full Text] [Related]
59. Identification of Novel Somatic
Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
[TBL] [Abstract][Full Text] [Related]
60. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]